Petros Pharmaceuticals Inc Stock

$0.35

12.90% day before yesterday

Nasdaq, Dec 27, 10:19 pm CET

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Overview Dividends Analysts Charts News Strategies

Petros Pharmaceuticals Inc Stock price

$0.35

-43.15 99.19% 5Y

Nasdaq, Closing price Fri, Dec 27 2024

+0.04 12.90%

ISIN

US71678J1007

Symbol

PTPI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Pharmaceuticals

Key metrics

Market capitalization	$3.51m
Enterprise Value	$4.80m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	0.69
P/S ratio (TTM) P/S ratio	0.50
P/B ratio (TTM) P/B ratio	1.13
Revenue (TTM) Revenue	$6.98m
EBIT (operating result TTM) EBIT	$-9.82m
Free Cash Flow (TTM) Free Cash Flow	$-6.94m
Cash position	$3.89m
EPS (TTM) EPS	$-6.21
P/S forward	0.58
EV/Sales forward	0.81
Short interest	2.19%

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

Get Started for Free Today

Petros Pharmaceuticals Inc Stock Analysis

Unlock Scores for Free

??

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

1x Buy

100%

More details on Analyst Estimates Including Price Targets

1 Analyst has issued a forecast Petros Pharmaceuticals Inc:

Buy

100%

Analyst Estimates with Stock Price Targets

Financial data from Petros Pharmaceuticals Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	6.98 6.98	81% 81% 100%
- Direct Costs	5.75 5.75	10% 10% 82%
Gross Profit	1.23 1.23	149% 149% 18%
- Selling and Administrative Expenses	5.81 5.81	11% 11% 83%
- Research and Development Expense	1.75 1.75	17% 17% 25%
EBITDA	-6.33 -6.33	36% 36% -91%
- Depreciation and Amortization	3.49 3.49	18% 18% 50%
EBIT (Operating Income) EBIT	-9.82 -9.82	30% 30% -141%
Net Profit	-13 -13	42% 42% -182%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Petros Pharmaceuticals Inc Stock News

Neutral

Accesswire

●

10 days ago

Petros Pharmaceuticals Featured in “New Era of Healthcare, AI, Data and Consumer Empowerment”

Company positions itself for new innovation utilizing AI and quantum computing to help expand patient access to drugs via OTC access NEW YORK, NY / ACCESSWIRE / December 19, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ("OTC") drug development programs, today announced that in...

Neutral

Accesswire

●

12 days ago

Proprietary Technology Addressing the Rx-to-OTC Switch Self-Care Market Valued at over $38 Billion annually

Working to identify quantum computing partnerships to strengthen our AI technology to include critical health records to better enable Rx to OTC switch candidates across multiple indications NEW YORK, NY / ACCESSWIRE / December 17, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over the counter ...

Neutral

Accesswire

●

4 months ago

Petros Pharmaceuticals Executes Successful Initial Test for App Comprehension as Part of FDA Pathway for Over-the-Counter Access for STENDRA(R) (avanafil)

Company is currently conducting larger scale comprehension test to confirm results in compliance with FDA discussions NEW YORK, NY / ACCESSWIRE / September 11, 2024 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI) ("Petros" or the "Company"), a company focused on expanding consumer access to medication through over-the-counter ("OTC") drug development programs, today announced results of an initial...

More Petros Pharmaceuticals Inc News

Company Profile

Petros Pharmaceuticals, Inc. is a pharmaceutical company focused on men's health therapeutics. Its commercial capabilities include sales, marketing, regulatory and medical affairs, finance, trade relations, pharmacovigilance, market access relations, manufacturing, and distribution. The firm operates through Prescription Medications and Medical Devices segments. The Prescription Medications segment consists primarily of Stendra, which is sold generally in the United States. The Medical Devices segment includes vacuum erection devices, which are sold domestically and internationally. The company was founded on May 14, 2020 and is headquartered in New York, NY.

Head office	United States
CEO	John Shulman
Employees	21
Website	www.petrospharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now